Navigation Links
GPhA Praises President Obama's Support for Safe and Affordable Biogenerics as Critical Solution to America's Ailing Health Care System

ARLINGTON, Va., Feb. 26 /PRNewswire/ -- The Generic Pharmaceutical Association (GPhA) today applauded President Obama's budget proposal for including a workable approval pathway for biogenerics that will substantially reduce health care costs by increasing access to quality care at affordable prices. The President's budget proposal would ensure that this process mirrors the proven Hatch-Waxman market exclusivity model, by ensuring that brand companies cannot extend exclusivity using "ever-greening."

"For patients across the country suffering from cancer, diabetes and other diseases, the support stated by President Obama today for a workable biogenerics approval pathway is lifesaving news. With countless patients struggling to pay the high costs of brand biopharmaceuticals, an approval pathway for safe, effective and affordable biogeneric medicines that provides access sooner rather than later is desperately needed. GPhA applauds the President's budget message specifically stating that a workable scientific, regulatory and legal pathway with exclusivity provisions consistent with the Hatch-Waxman model must be enacted. The exclusivity provisions of Hatch-Waxman have been a successful model, fostering innovation and competition while saving hundreds of billions of dollars, and this same success can be achieved with biogenerics," stated GPhA President and CEO Kathleen Jaeger.

"GPhA, AARP and numerous employers, labor, consumer and other organizations have consistently called for the creation of a workable approval pathway for biogenerics. We are pleased that the budget proposal specifically calls for: (1) creation of such a pathway; (2) biologic market exclusivity incentives consistent with 'the principles in the Hatch-Waxman law for traditional products;' and (3)'brand biologic manufacturers would be prohibited from reformulating existing products into new products to restart the exclusivity process, a process known as ever-greening.' The President clearly recognizes that unprecedented and unwarranted ever-greening provisions will only delay patient access to needed medicines and do nothing to lower health care costs.

"Controlling health care costs is a key component of the President's health care reform agenda and a critical step to putting our economy back on track. It is anticipated that by 2012, nearly half of all prescription drugs in the United States will be biologic products. As our elected officials grapple with serious economic and health care challenges, increasing access to generic and biogeneric medicines will significantly reduce health care costs and strengthen the availability of high quality health care," Jaeger concluded.

GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk active pharmaceutical chemicals, and suppliers of other goods and services to the generic drug industry. Generics represent 67% of the total prescriptions dispensed in the United States, but only 20% of all dollars spent on prescription drugs. For more information about the industry, visit

SOURCE The Generic Pharmaceutical Association (GPhA)
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AHIP Praises Bipartisan Senate Vote on Mental Health Parity
2. Union President Praises Hillary Clintons Health Plan
3. AIDS Action Council Praises Release of Latest State of AIDS in Black America Report
4. Lung Cancer Alliance Praises Congressional Call for Increased Commitment to Fund Lung Cancer Research
5. Bishops Conference Praises Senate Introduction of Pregnant Women Support Act
6. American Life League Praises Colorado Efforts to Stop Planned Parenthood Abortion Facility
7. Alliance for Quality Nursing Home Care Praises CMS Release of Updated Special Focus Facilities (SFF) List
8. Blunt Praises Presidents Plan to Save Medicare
9. FRC Action Praises John McCains Pro-Life Comments
10. Consumer Watchdog Praises CA HMO Regulators Promise to Reinstate Health Coverage for Wrongfully Cancelled Patients; Cautions That All Health Costs During Gap Must be Covered
11. USCCB Official Praises Senate Passage of Genetic Information Nondiscrimination Act
Post Your Comments:
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... HILLS, Calif. , June 23, 2016 Any ... the many challenges of the current process. Many of them ... because of the technical difficulties and high laboratory costs involved. ... have to offer it at such a high cost that ... afford it. Dr. Parsa Zadeh , founder ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... offering. The current unmet ... for MedImmune to enter. The US ageing population creates a ... considerable growth for effective anti-influenza medications. The introduction of a ... development is still in its infancy. Key ...
Breaking Medicine Technology: